Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of JNJ-56021927 Tablet Formulations vs Capsule in Healthy Men
NCT02031666Phase 1Completed
- Sponsor
- Aragon Pharmaceuticals
- Start
- Dec 2013
- Primary completion
- Apr 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apalutamide in prostate cancer (PCa) (8 arms), sponsored by Aragon Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 57, Time to Reach Maximum Observed Plasma Concentration at Day 57 and 10 more. Started Dec 2013; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02031666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031666.